Authorized purpose: Adjunctive review of MR prostate images and biopsy findings for prostate segmentation, lesion evaluation, quantification, documentation, and pre-planning biopsy or soft-tissue-ablation procedures.
Clinical role
Helps the user segment the prostate on MR images, evaluate and document lesions, and pre-plan biopsy or soft tissue ablation; the user thresholds a cancer map to set the lesion boundary and exports reviewed, verified plans to compatible systems.
Images and patients
MRI · Prostate
Key limitation
Keep in mind: Lesion-characterization functions are for pathology-confirmed GGG >= 2 lesions with corresponding biopsy coordinates uploaded; results support interpretation by a trained physician.
Clinical detailsPurpose, workflow fit, evidence, and safety record
Workflow navigation pilot
Workflow role has not yet been reviewed for this navigation pilot.
A tag identifies a documented role; it does not establish compatibility or local acceptance. Methods and sources
What does this software do?Authorized purpose: Adjunctive review of MR prostate images and biopsy findings for prostate segmentation, lesion evaluation, quantification, documentation, and pre-planning biopsy or soft-tissue-ablation procedures.
Which images or clinical context are in scope?Modality: MRI Anatomy or clinical context: Prostate Input: Prostate MR images plus biopsy findings, pathology, clinical data, and uploaded biopsy coordinates for lesion characterization.
Who uses it?Intended users: Physicians trained in the oncological workflow.
What does the software produce?Output: Prostate segmentation, lesion contours, a voxel-level cancer map, an Encapsulation Confidence Score, measurements, 3D visualization, and reviewed/exportable planning information.
What is its most important limitation?Key limitation: Lesion-characterization functions are for pathology-confirmed GGG >= 2 lesions with corresponding biopsy coordinates uploaded; results support interpretation by a trained physician.
Clinical takeaway. Clinical role: Adjunctive review of MR prostate images and biopsy findings for prostate segmentation, lesion evaluation, quantification, documentation, and pre-planning biopsy or soft-tissue-ablation procedures.
Evidence takeaway. Evidence from the reviewed source record: FDA packet reports standalone prostate-segmentation testing on 137 patients, lesion-contouring testing on 50 pathology cases, and an MRMC study with 10 practicing urologists or radiologists; reported assisted-contour sensitivity was 97.4% versus 38.2% for standard-of-care contours.
Evidence context
Evidence context not reviewed for this FDA record.
Public-label constraints
Label constraints have not been reviewed for this exact FDA record. Unknown is not all ages or evidence of unsuitability.
Public-label constraints, not patient-level eligibility or a medical recommendation. Training and evaluation populations are separate. Read the original labeling and confirm the exact release and protocol.
Purpose
Adjunctive review of MR prostate images and biopsy findings for prostate segmentation, lesion evaluation, quantification, documentation, and pre-planning biopsy or soft-tissue-ablation procedures.
Exact FDA submission
Checked 2026-09-19
Clinical-use display mirrors the exact FDA-supported purpose reconciled in this remediation finding.
Helps the user segment the prostate on MR images, evaluate and document lesions, and pre-plan biopsy or soft tissue ablation; the user thresholds a cancer map to set the lesion boundary and exports reviewed, verified plans to compatible systems.
Exact FDA submission
Checked 2026-11-14
Packet wording: "designed to support the prostate oncological workflow by helping the user with the segmentation of MR image features, including the prostate; in the evaluation, quantification, and documentation of lesions; and in pre-planning for diagnostic and interventional procedures such as biopsy and/or soft tissue ablation." … "A user selects a threshold for the cancer map to create a boundary of the lesion.". Read from the exact FDA decision document on 2026-11-14.
Prostate segmentation, lesion contours, a voxel-level cancer map, an Encapsulation Confidence Score, measurements, 3D visualization, and reviewed/exportable planning information.
Used in a clinical setting; lesion characterization functions are for patients with a pathology-confirmed Gleason Grade Group (GGG) ≥ 2 lesion and uploaded biopsy coordinates; the FDA document does not specify a facility type.
Exact FDA submission
Checked 2026-11-14
Packet wording: "The device is intended to be used by physicians trained in the oncological workflow in a clinical setting for planning and guidance for clinical, interventional, diagnostic, and/or treatment procedures of the prostate." … "The Avenda Health AI Prostate Cancer Planning Software’s lesion characterization functions are intended for use on patients with a pathology-confirmed Gleason Grade Group (GGG) ≥ 2 lesion and for whom corresponding biopsy coordinate information have been uploaded.". Read from the exact FDA decision document on 2026-11-14.
Lesion-characterization functions are for pathology-confirmed GGG >= 2 lesions with corresponding biopsy coordinates uploaded; results support interpretation by a trained physician.
FDA packet reports standalone prostate-segmentation testing on 137 patients, lesion-contouring testing on 50 pathology cases, and an MRMC study with 10 practicing urologists or radiologists; reported assisted-contour sensitivity was 97.4% versus 38.2% for standard-of-care contours.
Exact FDA submission
Checked 2026-09-19
Submission-reported testing with comparator context preserved.
Metrics are shown only when they are tied to a source, endpoint, population, and tested product version. Candidate literature without exact product and version linkage is not shown as product evidence.
Evidence summary
FDA packet reports standalone prostate-segmentation testing on 137 patients, lesion-contouring testing on 50 pathology cases, and an MRMC study with 10 practicing urologists or radiologists; reported assisted-contour sensitivity was 97.4% versus 38.2% for standard-of-care contours.
FDA source
Exact FDA submission
Checked 2026-09-19
Submission-reported testing with comparator context preserved.
Values reported in the exact-submission materials. Consult the linked source for endpoint, threshold, population, and confidence interval before comparison.
Values reported in the exact-submission materials. Consult the linked source for endpoint, threshold, population, and confidence interval before comparison.
No contextualized exact-version metric has completed evidence review. Regulatory-document values, when available, are shown above with their limitations.
Avenda Health AI Prostate Cancer Planning Software regulatory performance study summary
DesignStand-alone performance and reader study (ACR AI Central category)
PopulationPopulation described in the exact-submission ACR model card
Scopeexact submission
Tested versionExact product version not reported; regulatory study summarized for FDA submission K221624
Samplen=137
IndependenceIndependence not established
K221624
ACR AI Central summarizes the regulatory study; consult the exact FDA materials before comparative use.
Recall and adverse-event records are shown only after product matching. Adverse-event reports do not establish incidence or causality.
Postmarket safety review
The exact-identifier FDA recall query returned no native recall record for K221624. This limited result does not establish absence of recalls or other safety information and does not cover later versions, family records, MAUDE reports, corrections, or field notices.
IT implementationDeployment, interfaces, data handling, and support
System and version relationships
Match the AI release, system build, configuration and region. Source documentation does not establish acceptance of an installed system.
No specific system/version pairing has completed review for this FDA record. A broad DICOM or product-family statement does not establish a named viewer build's support.
Public source context, not tested interoperability. Each hop needs its own release/configuration evidence. Missing or unavailable routes are not documented incompatibility. All local tests are planned, not passed; no installed-system acceptance is recorded.
Acquisition/source → routing → AI processing → returned objects → viewer/worklist/report → support owner
No specific route context has been source-reviewed for this record. Obtain both endpoint builds and documents; this is not a finding of incompatibility.
Acquisition/source
Source context, not route validation: Prostate MR images plus biopsy findings, pathology, clinical data, and uploaded biopsy coordinates for lesion characterization.
Scope: Exact FDA submission. FDA indications and device description.
Confirm scanner/model, protocol, series completeness and both software builds.
Source context, not route validation: The exact FDA package describes DICOM compatibility for MR scans and export of findings as DICOM, planning assets, or an intervention plan for supported systems, in a supported file format that can be imported into a compatible interventional or biopsy system. Interface versions and local compatibility require confirmation.
Scope: Exact FDA submission. Packet wording: "DICOM Compatible Yes Yes Same as the predicate device. Type of Scans MR, DICOM-compatible MR, DICOM-compatible Same as the predicate device." … "Export Formats: ● DICOM ● DICOM Similar – both devices allow export of findings for use in ● Planning assets future oncological steps. ● Intervention plan for supported systems". Read from the exact FDA decision document on 2026-11-14; this is the release-level description, not current commercial configuration.
Name gateways, destinations, transfer rules and failure visibility; a DICOM statement does not prove a route.
Source context, not route validation: The exact FDA package describes the platform and architecture as a cloud-only solution and characterizes the device as web-based software. Current hosting, data flow, and commercial configuration require vendor confirmation.
Scope: Exact FDA submission. Packet wording: "Platform/Architecture Cloud-only solution Software-only platform Similar – both devices are Web-based software devices.". Read from the exact FDA decision document on 2026-11-14; this is the release-level description, not current commercial configuration.
Confirm processing location, queue ownership, exclusions and exact AI build.
Source context, not route validation: Prostate segmentation, lesion contours, a voxel-level cancer map, an Encapsulation Confidence Score, measurements, 3D visualization, and reviewed/exportable planning information.
Scope: Exact FDA submission. FDA device description and indications.
Confirm object classes, units, references and whether findings, overlays or measurements reach their intended destination.
Unresolved route: Prostate segmentation, lesion contours, a voxel-level cancer map, an Encapsulation Confidence Score, measurements, 3D visualization, and reviewed/exportable planning information.
Scope: Exact FDA submission. FDA device description and indications.
Confirm the named viewer/worklist/report build, display behavior and report transfer. Output support alone does not establish this endpoint. The displayed source describes output, not validated end-to-end delivery.
Unresolved route: Not established for the exact route.
Scope: Scope not established.
Name the local, platform and AI supplier support owners and escalation path.
Planned local route tests
No tests below have been performed or accepted.
Patient/study identity (planned). Use approved non-patient test data to verify identifiers, accession and result-to-study linkage at every hop.
Study completeness (planned). Test missing views/series, partial transfer, late arrivals, priors and unsupported acquisition inputs; confirm explicit refusal or fallback.
Ordering and duplicates (planned). Send out-of-order, repeated and corrected studies; verify worklist order, deduplication and no misleading stale results.
Report transfer (planned). Verify output object types, annotations, units, report content, destination and availability of original images.
Access (planned). Verify authorized roles, audit trail, denied access and support ownership at each destination.
Latency and failures (planned). Agree a workload and turnaround target; test queues, timeouts, missing results and fallback reading.
Updates and rollback (planned). Define version change control, revalidation triggers, stop-use criteria and a tested rollback route.
Local implementation checklist
Agree the evidence and acceptance owner with your team and suppliers. Checkmarks apply to this page only and are not acceptance receipts.
The exact FDA package describes the platform and architecture as a cloud-only solution and characterizes the device as web-based software. Current hosting, data flow, and commercial configuration require vendor confirmation.
Exact FDA submission
Checked 2026-11-14
Packet wording: "Platform/Architecture Cloud-only solution Software-only platform Similar – both devices are Web-based software devices.". Read from the exact FDA decision document on 2026-11-14; this is the release-level description, not current commercial configuration.
The exact FDA package describes DICOM compatibility for MR scans and export of findings as DICOM, planning assets, or an intervention plan for supported systems, in a supported file format that can be imported into a compatible interventional or biopsy system. Interface versions and local compatibility require confirmation.
Exact FDA submission
Checked 2026-11-14
Packet wording: "DICOM Compatible Yes Yes Same as the predicate device. Type of Scans MR, DICOM-compatible MR, DICOM-compatible Same as the predicate device." … "Export Formats: ● DICOM ● DICOM Similar – both devices allow export of findings for use in ● Planning assets future oncological steps. ● Intervention plan for supported systems". Read from the exact FDA decision document on 2026-11-14; this is the release-level description, not current commercial configuration.
ACR AI Central provides an exact-submission model card for Avenda Health AI Prostate Cancer Planning Software; FDA labeling remains controlling for clinical use, limitations, and performance.
Sources & review detailsFDA identity, research record, source ledger, and history
Regulatory identity
FDA record and catalog context
The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.
This audit distinguishes completed source review from fields that have not yet been researched.
Exact FDA record reviewedStatus
2026-09-20Last searched
27Fields reviewed
10Source classes checked
0Screened PubMed leads
0Screened trial leads
0Unreviewed FDA recall leads
The refreshed discovery snapshot contains no PubMed or ClinicalTrials.gov candidates; no external evidence was promoted. The current discovery snapshot contains 0 PubMed and 0 ClinicalTrials.gov candidate records; its dated, count-matched human screening remains current. Unlinked candidates remain quarantined. Native FDA recall identifiers produced 0 postmarket candidate records; 0 have been reviewed (0 published, 0 rejected) and 0 remain unreviewed.
Candidate leads were screened against the exact product and tested version. Unlinked records remain quarantined.
Source classes: fda ai list, fda decision summary, acr ai central product, fda device recall, literature index, trial registry, fda decision summary packet, pubmed, clinical trials, openfda device recall
Field review details
Recorded state, verification date, notes and sources for fields without a publishable value. Conflicting records stay explicitly unsettled here; no plain settled value is shown for them.
Public pricing: Not verified - checked 2026-09-09 - Exact FDA submission
No public price or quote for the exact K221624 configuration was established in this review.
Pricing model: Not yet reviewed
Setup and integration fees: Not yet reviewed
Recurring fees: Not yet reviewed
Minimum commitment: Not yet reviewed
Contract duration: Not yet reviewed
Renewal terms: Not yet reviewed
Cancellation terms: Not yet reviewed
Support and service terms: Not yet reviewed
Trial or pilot terms: Not yet reviewed
Reimbursement: Not publicly available - checked 2026-09-09 - Exact FDA submission
No exact-product payer policy, coding instruction, or payment determination was established; eligibility must be evaluated by payer, site of service, and use case.
Data hosting location: Not yet reviewed
Data retention: Not yet reviewed
Documented data use: Not yet reviewed
Hardware requirements: Not yet reviewed
Network requirements: Not yet reviewed
Identity and access: Not yet reviewed
Security: Not verified - checked 2026-09-09 - Exact FDA submission
Exact-release security controls, data retention, hosting boundaries, and scoped assurance documentation require vendor confirmation.
Installation timeline: Not yet reviewed
Training: Not verified - checked 2026-09-09 - Exact FDA submission
Current training prerequisites, competency checks, and support commitments for the exact configuration require vendor confirmation.
Monitoring: Not verified - checked 2026-09-09 - Exact FDA submission
Current drift, quality, uptime, alert, escalation, and incident-response commitments for the exact configuration require vendor confirmation.
Authorized purpose: Assist trained radiologists and urologists in reviewing and analyzing prostate MR studies through semi-automatic prostate outlining, multiparametric visualization, and related measurements and reporting; patient-management decisions must not rely on the software alone.
Authorized purpose: PROView is an aiding tool for the clinicians to review multi-parametric prostate MR images following PI-RADS guidelines. It displays acquired and reformatted data for visualization and provides tools for assessment of the prostate gland volume and findings analysis in patients with known or suspected prostate lesions. Measurements and associated scoring are included in a report for communication to referring physicians.
Authorized purpose: Quantib Prostate is image post-processing software for processing, visualizing, and editing prostate MRI images. It supports registered multiparametric-MRI viewing, optional combined-image visualization, semi-automatic anatomical segmentation, volume computation, manual editing, and a structured PI-RADS workflow to assist trained medical professionals interpreting prostate MR studies; diagnosis should not be made solely from its analysis.
Authorized purpose: RSI-MRI+ is indicated for use as automatic post-acquisition image processing software for analysis of diffusion-weighted and anatomical magnetic resonance imaging data. RSI-MRI+ is intended for automatic fusion of derived diffusion-weighted MRI data with anatomical T2-weighted MR images. RSI-MRI+ is additionally intended to provide automatic prostate segmentation, quantification, and reporting of derived image metrics.
Copy this public context and add the field, proposed wording and original source before sending. Nothing here is submitted automatically. Form-specific prefill has not been verified.
Permission to display a submission is not evidence verification. A submission enters editorial review; it does not approve a public change. Form availability, data entry, receipt, review and publication are separate steps. Data entry and receipt remain unverified.
Accepted repository change history
No entry has been added to this scoped change history for this record. This is not proof that the record never changed.